Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Oral Oncol. 2019 Oct 10;98:147–155. doi: 10.1016/j.oraloncology.2019.09.005

Figure 5.

Figure 5.

MYB inhibitors suppress ACC cell lines viability in vivo. (a) Viability of early passage human UFACCH2 or murine ACC-like breast tumor UFBT cell lines after exposure to Celastrol at indicated concentrations or DMSO control for 48 hrs. Error bars represent standard deviations of four biological replicates. (b) Viability of control tumor cell lines that are not associated with MYB activation (3T3 and AsPC1) after 48 hrs exposure to Celastrol. (c) Viability (top panel) of UFBT (left) or UFH2 (right) cells, treated with 10 μM of inactivated TG3 analogue peptide or 10 μM MYBMIM. Error bars represent standard deviations of three biological replicates. Photomicrographs (bottom panel) after incubation with indicated peptide mimic inhibitors (UFBT, left and UFH2, right). (d) Viability of non-MYB-activated control tumor cells (3T3, AsPC1 and Panc-1) after exposure to 10 μM control TG3 or MYBMIM for 48 hrs. Error bars represent standard deviations of four biological replicates.